Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Twin Cities
Tampa Bay news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa Bay
Charlotte news in your inbox
Catch up on the most important stories affecting your hometown with Axios Charlotte
Harmid / Wikimedia Commons
A federal court in Pennsylvania — on behalf of the Justice Department's antitrust division — has issued a subpoena to an unnamed Baxter International employee as it pursues a criminal investigation into how Baxter has priced and sold its IV saline products, Baxter disclosed Friday. The company said in a statement to Axios that it is "cooperating" with the Justice Department and "believes it has responsibly priced these life-sustaining products."
Why this matters: The country faces a nationwide shortage of saline, the common IV fluid found in hospitals and other health care settings. An antitrust class-action lawsuit accuses Baxter and Hospira (now part of drug giant Pfizer) of intentionally creating a saline shortage so they could jack up prices. The companies control about 90% of the IV saline market. It's an ominous sign for a company when the federal government gets involved. The subpoena asks for internal Baxter documents and "communications with competitors."